MapLight Therapeutics (MPLT) Other Accumulated Expenses (2024 - 2025)
MapLight Therapeutics (MPLT) reported Other Accumulated Expenses of $521000.0 for Q4 2025, down 66.56% on a YoY basis from $1.6 million in Q4 2024, and down 75.54% sequentially from $2.1 million in Q3 2025.
MapLight Therapeutics (MPLT) Other Accumulated Expenses (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Other Accumulated Expenses data on file, last reported at $521000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Accumulated Expenses fell 66.56% year-over-year to $521000.0; the trailing twelve-month figure through Dec 2025 stood at $521000.0 (down 66.56% YoY), and the FY2025 full-year result was $521000.0, down 66.56% from the prior year.
- Other Accumulated Expenses eased to $521000.0 in Q4 2025, from $2.1 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $2.1 million in Q3 2025 to a low of $521000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,725.60 Bn | 68,725.31 Bn | - |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 472.73 Bn | 467.94 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.52 Bn | 116.27 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.74 Bn | 60.99 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - |
| 8 | Argenx Se | 56.42 Bn | 51.24 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.76 Bn | 37.76 Bn | - |
| 10 | MapLight Therapeutics | 121.18 Mn | 121.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 521,000.00 |
| Sep 30, 2025 | 2.13 Mn |
| Dec 31, 2024 | 1.56 Mn |